SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-24-009809
Filing Date
2024-02-01
Accepted
2024-02-01 16:15:34
Documents
61
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 10-K abio-20231231.htm   iXBRL 10-K 2058310
2 EX-19 abio-ex19.htm EX-19 106748
3 EX-23.1 abio-ex23_1.htm EX-23.1 3372
4 EX-31.1 abio-ex31_1.htm EX-31.1 12399
5 EX-31.2 abio-ex31_2.htm EX-31.2 12382
6 EX-32.1 abio-ex32_1.htm EX-32.1 10187
7 EX-97 abio-ex97.htm EX-97 47091
  Complete submission text file 0000950170-24-009809.txt   6562239

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT abio-20231231.xsd EX-101.SCH 896924
63 EXTRACTED XBRL INSTANCE DOCUMENT abio-20231231_htm.xml XML 755086
Mailing Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021
Business Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021 7209402200
ARCA biopharma, Inc. (Filer) CIK: 0000907654 (see all company filings)

IRS No.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 000-22873 | Film No.: 24587126
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)